Header Logo
Last Name

Dr Richard Kajubi

TitleStudy Coordinator
InstitutionInfectious Diseases Research Collaboration
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Richard is Medical Doctor and Research Scientist with over ten years of experience in active clinical practice and eight years in infectious diseases research activities with a keen interest in malaria and HIV/AIDS research focusing on optimization of therapy and drug-drug interactions.
    Previously, he served as a Medical Officer for Kilembe Mines Hospital for three years on large-scale USAID funded health systems strengthening projects with focus to HIV&AIDS care and treatment and general medical practice. He also worked as a Junior House Officer for Mulago Hospital for a year during Internship training with focus to research and general medical practice. In his current role as a Study Coordinator for the Infectious Diseases Research Collaboration (IDRC), he has taken lead in collaborative research in management, coordination, reporting, quality control and documentation of study activities in a number of malaria projects at the Tororo and Busia sites and contributed to various abstracts and publications. He’s also made several presentations both locally and internationally.
    Throughout his career, Richard has held positions that have required him to initiate, coordinate and manage the adaptation and dissemination of program strategies in various health related areas. He has experience working with diverse groups of stakeholders, including American Research Collaborators from University of California, San Francisco, Makerere University College of Health Sciences, the Ministry of Health (MoH) Uganda, District Health Management Teams, District Councils, and local communities to organize and conduct various research activities and program interventions through evidence-based practice. He has also earned additional training in project planning and management and is currently pursuing advanced training in Pharmacology and therapeutics.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Hughes E, Mwebaza N, Huang L, Kajubi R, Nguyen V, Nyunt MM, Orukan F, Mwima MW, Parikh S, Aweeka F. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women. J Acquir Immune Defic Syndr. 2020 Feb 01; 83(2):140-147. PMID: 31929402.
      View in: PubMed
    2. Whalen ME, Kajubi R, Chamankhah N, Huang L, Orukan F, Wallender E, Kamya MR, Dorsey G, Jagannathan P, Rosenthal PJ, Mwebaza N, Aweeka FT. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention. Clin Pharmacol Ther. 2019 Dec; 106(6):1310-1318. PMID: 31173649.
      View in: PubMed
    3. Briggs J, Ategeka J, Kajubi R, Ochieng T, Kakuru A, Ssemanda C, Wasswa R, Jagannathan P, Greenhouse B, Rodriguez-Barraquer I, Kamya M, Dorsey G. Impact of Microscopic and Submicroscopic Parasitemia During Pregnancy on Placental Malaria in a High-Transmission Setting in Uganda. J Infect Dis. 2019 07 02; 220(3):457-466. PMID: 30891605.
      View in: PubMed
    4. Lehane A, Were M, Wade M, Hamadu M, Cahill M, Kiconco S, Kajubi R, Aweeka F, Mwebaza N, Li F, Parikh S. Comparison on simultaneous caillary and venous parasite density and genotyping results from children and adults with uncomplicated malaria: a prospective observational study in Uganda. BMC Infect Dis. 2019 Jun 26; 19(1):559. PMID: 31242863.
      View in: PubMed
    5. Okiring J, Olwoch P, Kakuru A, Okou J, Ochokoru H, Ochieng TA, Kajubi R, Kamya MR, Dorsey G, Tusting LS. Household and maternal risk factors for malaria in pregnancy in a highly endemic area of Uganda: a prospective cohort study. Malar J. 2019 Apr 23; 18(1):144. PMID: 31014336.
      View in: PubMed
    6. Kajubi R, Ochieng T, Kakuru A, Jagannathan P, Nakalembe M, Ruel T, Opira B, Ochokoru H, Ategeka J, Nayebare P, Clark TD, Havlir DV, Kamya MR, Dorsey G. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. Lancet. 2019 Apr 06; 393(10179):1428-1439. PMID: 30910321.
      View in: PubMed
    7. Wallender E, Zhang N, Conrad M, Kakuru A, Muhindo M, Tumwebaze P, Kajubi R, Mota D, Legac J, Jagannathan P, Havlir D, Kamya M, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda. Antimicrob Agents Chemother. 2019 02; 63(2). PMID: 30530597.
      View in: PubMed
    8. Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis. 2018 09 14; 67(7):1079-1088. PMID: 29547881.
      View in: PubMed
    9. Huang L, Mwebaza N, Kajubi R, Marzan F, Forsman C, Parikh S, Aweeka FT. Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients. PLoS One. 2018; 13(8):e0202082. PMID: 30114201.
      View in: PubMed
    10. Jagannathan P, Kajubi R, Aweeka FT. Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction". Clin Pharmacol Ther. 2018 04; 103(4):571. PMID: 29322501.
      View in: PubMed
    11. Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Ruel T, Koss CA, Kakuru A, Mwebaza N, Kamya M, Havlir D, Dorsey G, Rosenthal PJ, Aweeka FT. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther. 2017 Sep; 102(3):520-528. PMID: 28187497.
      View in: PubMed
    12. Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, Gingrich D, Nyunt MM, Ssebuliba J, Mwebaza N, Aweeka FT, Parikh S. Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. Open Forum Infect Dis. 2016 Oct; 3(4):ofw217. PMID: 28018925.
      View in: PubMed
    13. Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis. 2016 08 01; 63(3):414-22. PMID: 27143666.
      View in: PubMed
    14. Nyunt MM, Nguyen VK, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Mwima MW, Achan J, Aweeka F, Parikh S, Mwebaza N. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1274-82. PMID: 26666942.
      View in: PubMed
    Kajubi's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Similar People Expand Description